Zimmer and Biomet announced today that the Federal Trade Commission has requested additional information on Zimmer’s announced purchase of Biomet.
The request was made under the notification requirements of the Hart-Scott-Rodino Antitrust Improvements Act. The effect of the request is to extend the waiting period imposed by the act until 30 days after Zimmer and Biomet have substantially complied with the request, unless that period is extended voluntarily by the parties or terminated sooner by the FTC, the announcement states.
In June, the European Commission paused review of the deal pending additional information. The two Warsaw-based orthopedic companies expect to close the $13.4 billion transaction in the first quarter of 2015.
Executives from both companies have also been appointed to manage their integration, Mass Device reported Tuesday.
Derek Davis, Zimmer chief accounting officer and vice president of finance, and Peggy Taylor, Biomet senior vice president of human resources, will head the integration management office, which was started to help the integration steering committee. The two will be responsible for integration measures such as communicating the intent of the integration and metrics that define success; establishing integration timelines, processes and templates; and providing direction to integration planning teams and escalating issues to the steering committee, according to a Zimmer filing under the Securities Exchange Act.
“Derek and Peggy are proven leaders with vast experience managing projects across their respective organizations. They will be integral in identifying best practices for the future combined company, while also ensuring that we seamlessly serve our respective customers and focus on our business objectives,” the filing states.
The filing names several other integration managers, noting they will focus on  functions such as finance, marketing and the companies’ business lines and operating regions.